MARKET

MGNX

MGNX

MacroGenics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

19.74
-0.80
-3.89%
After Hours: 20.49 +0.75 +3.80% 16:51 09/24 EDT
OPEN
20.51
PREV CLOSE
20.54
HIGH
20.87
LOW
19.73
VOLUME
345.15K
TURNOVER
--
52 WEEK HIGH
36.48
52 WEEK LOW
18.16
MARKET CAP
1.21B
P/E (TTM)
-8.7345
1D
5D
1M
3M
1Y
5Y
Should You Consider Selling Your MacroGenics (MGNX) Shares?
Wasatch Global Investors, an investment management firm, published its “Wasatch Ultra Growth Fund” second quarter 2021 investor letter – a copy of which can be downloaded here. A quarterly return of 6.02% was recorded by the fund’s investor class for the Q...
Insider Monkey · 3d ago
Company News for Sep 17, 2021
Companies in The News Are: F,WYNN,LVS,MGNX
Zacks · 09/17 12:48
56 Biggest Movers From Yesterday
   
Benzinga · 09/17 09:28
Mid-Afternoon Market Update: Dow Falls 70 Points; Aerie Pharmaceuticals Shares Plunge
Toward the end of trading Thursday, the Dow traded down 0.20% to 34,745 while the NASDAQ fell 0.03% to 15,157.61. The S&P also fell, dropping 0.21% to 4,471.34.
Benzinga · 09/16 18:46
MacroGenics Shares Fall After MGC018 Data Fails To Impress At ESMO Presentation
MacroGenics Inc (NASDAQ: MGNX) 
Benzinga · 09/16 18:12
Mid-Day Market Update: Gold Drops Over 2%; Leap Therapeutics Shares Jump
Midway through trading Thursday, the Dow traded down 0.74% to 34,557.75 while the NASDAQ fell 0.67% to 15,060.25. The S&P also fell, dropping 0.79% to 4,445.34.
Benzinga · 09/16 16:38
Mid-Morning Market Update: Markets Down; US Retail Sales Unexpectedly Increase in August
Following the market opening Thursday, the Dow traded down 0.45% to 34,657.69 while the NASDAQ fell 0.66% to 15,061.97. The S&P also fell, dropping 0.62% to 4,453.04.
Benzinga · 09/16 14:20
Neuroblastoma Drugs Market By Delivery, Type, Systems, End-User 2028
Research Nester published a report titled "- Global Demand Analysis and Opportunity Outlook 2020-2028" which delivers detailed overview of the neuroblastoma drugs market in terms of market segmentation by drug type, by mechanism type, by treatment type, by...
AmericaNewsHour · 09/16 13:33
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MGNX. Analyze the recent business situations of MacroGenics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MGNX stock price target is 36.25 with a high estimate of 50.00 and a low estimate of 17.00.
EPS
Institutional Holdings
Institutions: 211
Institutional Holdings: 67.57M
% Owned: 110.58%
Shares Outstanding: 61.11M
TypeInstitutionsShares
Increased
54
5.76M
New
18
2.56M
Decreased
49
3.49M
Sold Out
42
4.34M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Non-Executive Chairman/Independent Director
Paulo Costa
President/Chief Executive Officer/Director
Scott Koenig
Chief Financial Officer/Senior Vice President/Secretary
James Karrels
Senior Vice President/Chief Scientific Officer
Ezio Bonvini
Senior Vice President
Stephen Eck
Senior Vice President
Eric Risser
Senior Vice President
Thomas Spitznagel
Vice President/General Counsel
Jeffrey Peters
Vice President/Controller/Treasurer
Lynn Cilinski
Independent Director
Karen Ferrante
Independent Director
Kenneth Galbraith
Independent Director
Edward Hurwitz
Independent Director
Scott Jackson
Independent Director
Federica O'Brien
Independent Director
Jay Siegel
Independent Director
David Stump
No Data
About MGNX
MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies. It has a pipeline of product candidates in human clinical testing, primarily as treatments for different types of cancers, which are created using its technology platforms. Its clinical product candidate, margetuximab, has been enhanced using its Fc Optimization platform. The Company is also developing several product candidates targeting B7-H3, a protein in the B7 family of immune regulator proteins. The Company's product candidates also include enoblituzumab and MGD009, MGC018, MGD006 (flotetuzumab), MGD007, MGD011 (duvortuxizumab), PF-06671008 and MGD010.

Webull offers kinds of MacroGenics Inc stock information, including NASDAQ:MGNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MGNX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MGNX stock methods without spending real money on the virtual paper trading platform.